Document is current
Any future updates will be listed below
-
Authors
Takvorian, Samuel U.
Bekelman, Justin
Beidas, Rinad S.
Schnoll, Robert
Clifton, Alicia B. W.
Salam, Tasnim http://orcid.org/0000-0002-0646-0134
Gabriel, Peter
Wileyto, E. Paul
Scott, Callie A.
Asch, David A.
Buttenheim, Alison M.
Rendle, Katharine A.
Chaiyachati, Krisda
Shelton, Rachel C.
Ware, Sue
Chivers, Corey
Schuchter, Lynn M.
Kumar, Pallavi
Shulman, Lawrence N.
O’Connor, Nina
Lieberman, Adina
Zentgraf, Kelly
Parikh, Ravi B.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P50CA244690)
- License Information
-
More Information
Article History
Received: 23 August 2021
Accepted: 6 September 2021
First Online: 25 September 2021
Declarations
:
: This study is approved by the University of Pennsylvania IRB (protocol #844816) and is registered on ExternalRef removed under the title “Effect of Behavioral Nudges on Serious Illness Conversation Documentation (SPP2)” and registration number NCT04867850.
: Not applicable
: Dr. Takvorian has provided consultation to Genentech and receives funding support from Pfizer unrelated to this research. Dr. Schnoll has provided consultation to Pfizer, GlaxoSmithKline, and Curaleaf and has received free medication and placebo from Pfizer for past studies. Dr. Asch is a partner at VAL Health. Dr. Beidas receives royalties from Oxford University Press. She has provided consultation to the Camden Coalition of Healthcare Providers. She currently consults to United Behavioral Health and serves on the Clinical and Scientific Advisory Board for Optum Behavioral Health. Dr. Bekelman reports grants from Pfizer, grants from UnitedHealth Group, grants from Embedded Healthcare, grants from Blue Cross Blue Shield of North Carolina, personal fees from UnitedHealthcare, personal fees from CMS, personal fees from NCCN, personal fees from Optum, personal fees from CVS Health, and personal fees from Astrazeneca (indirect via NCCN), outside the submitted work.
